Results 161 to 170 of about 21,658 (255)

Beyond Platelet Count: Rethinking Platelet-Rich Plasma Efficacy Through Growth Factor Biology and Functional Quality. [PDF]

Life (Basel)
Costa FR, Purita J, Martins R, Pires L, Mahmood A, Santos GS, Kruel A, Protásio Netto J, Lana JF.   +8 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Evaluation on Selective and Differential Medium (AFPA) for Enumeration of Aspergillus flavus in Imported Foods

Food Hygiene and Safety Science (Shokuhin Eiseigaku Zasshi), 1994
SUZUKI, Meiko, NARITA, Noriko, KIKUCHI, Yutaka, ICHINOE, Masakatsu   +3 more
openaire   +2 more sources

Seasonal Shifts in the Microbiota of Wild-Caught Danish <i>Carcinus maenas</i>. [PDF]

Microorganisms
Chinellato L, Hansen LT, Kragh ML, Gringer N, Bang-Berthelsen CH.   +4 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Can Mimosa pudica Plants Enumerate Light Exposure Events? [PDF]

Cogn Sci
Vishton PM, Bartosh PJ.
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Use of a Differential Culture Medium for the Enumeration of Zygosaccharomyces bailii, Saccharomyces cerevisiae and Pichia membranifaciens in Wine [PDF]

, 2003
Schuller, Dorit Elisabeth, Côrte-Real, Manuela, Leão, Cecília   +2 more
openaire   +2 more sources

Role of innate immune and inflammatory signaling in West Nile virus tropism and neuronal and glial cell death. [PDF]

Sci Rep
Chaillot V, Piumi F, Gorna K, Berry N, Richardson J, Benchoua A, Coulpier M.   +6 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source